Abstract
Metastatic breast cancer (MBC) remains the second cause of cancer death in women,
despite improvements in early breast cancer detection and treatments, with a 5-year
survival of only 27%. Patients with MBC involving the liver have a 5-year survival
of only 3.8 to 12%. Systemic therapy is the cornerstone for the treatment of MBC according
to the National Comprehensive Cancer Network (NCCN) guidelines. Radioembolization
is not specifically prescribed by the NCCN guidelines in the treatment of MBC liver
metastasis, but is an emerging therapy with some promising results. The two primary
reasons to offer radioembolization would be to prolong life and to palliate and improve
quality of life. We review here the indications, contraindications, technique, case
examples, and unanswered questions.
Keywords
metastatic breast cancer - radioembolization - metastatic disease
